ReviewCureus2026
Persistent Cognitive Dysfunction in Postural Orthostatic Tachycardia Syndrome: A Scoping Review of Neural Mechanisms, Interventions, and Critical Research Gaps.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postural orthostatic tachycardia syndrome (POTS) is widely treated as a cardiovascular-autonomic syndrome, but cognitive dysfunction is a disabling and poorly treated clinical phenomenon. This scoping review discusses why brain fog, impaired attention, slowed processing speed, memory difficulties, word-finding issues, and executive dysfunction may persist despite conventional pharmacological and non-pharmacological POTS treatments. The study uses a structured scoping review design to synthesize 18 peer-reviewed sources that meet the inclusion criteria, with publication dates between 2013 and 2025, across the domains of mechanistic, clinical, treatment, rehabilitation, and interventional studies. The evidence can be grouped into three principal mechanistic pathways: cerebral hypoperfusion and hemodynamic dysfunction; autonomic dysregulation and sympathetic overactivation; and neuroinflammation, autoimmune responses, mast cell activation, and microclot formation. The review found that abnormal cerebral blood flow (CBF) was reported in 61% of 56 POTS patients with cognitive dysfunction, and that sustained cognitive stress induced a greater reduction in CBF velocity in POTS patients than in controls, at approximately 7.8% and 1.8%, respectively. Current therapies, including beta-blockers, ivabradine, midodrine, exercise, salt and fluid loading, compression garments, cognitive behavioral therapy (CBT), and sleep management, rarely use cognition as a primary endpoint. Findings suggest that persistent cognitive dysfunction in POTS may reflect incomplete alignment between neurological mechanisms and cardiovascular-centered care, requiring validated cognitive outcomes and multimodal trials combining biological, autonomic, and rehabilitative interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.